Intradiscal cell therapy represents a reasonable bridge between conservative care and surgical fusion for chronic, localised disc degeneration with moderate pain (VAS 5–8) refractory to physiotherapy and epidural injection. Cost (€5,000–7,000 per disc) is substantially less than fusion surgery (€20,000–30,000) and avoids surgical immobility and adjacent-segment degeneration risks. Probability of ≥20% pain reduction (~55–60%) justifies consideration for motivated patients. Limitations: durability is uncertain (requiring possible re-treatment); structural regeneration is unproven; and advanced degeneration with neurological deficits may require surgery regardless. Best-fit candidates are age 35–65 with symptomatic single-level or dual-level disc disease, preserved disc height, and strong motivation to defer or avoid fusion.
Chronic back pain frequently stems from degenerative disc disease—loss of hydration and structural integrity in intervertebral discs—compounded by facet joint arthritis and paraspinal muscle atrophy. Stem cell strategies target the nucleus pulposus (disc centre), where placental mesenchymal stem cells (MSCs) may regenerate proteoglycan matrix and restore biomechanical function. Exosomes derived from stem cells penetrate the avascular disc environment and deliver anti-inflammatory proteins that suppress catabolic pathways. Unlike surgical fusion, which immobilises segments, cell-based approaches aim to restore disc biology whilst preserving motion. MSCs also modulate neuropathic pain via immune suppression, addressing pain signalling independent of structural restoration. Thirty-five registered trials globally investigate disc regeneration and pain outcomes; two actively recruit new participants.
Am I a candidate? → · Back & Disc Degeneration: full overview → · Back & Disc Degeneration cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.
Get an honest assessment